OB is a biotechnology company committed to developing innovative scfv antibody based therapies for the treatment of patients with cancers.
Optieum Biotechnologies's investors include ANRI, UntroD Capital, Keio Innovation Initiative, Iyogin Capital, Vision Incubate.
Optieum Biotechnologies is headquartered in Matsuyama-shi, Japan.
OB is a biotechnology company committed to developing innovative scfv antibody based therapies for the treatment of patients with cancers.
Optieum Biotechnologies is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Optieum Biotechnologies — Funding & Investors." VCBacked, April 1, 2026, https://www.vcbacked.co/company/optieum-biotechnologies. Accessed September 30, 2026.
VCBacked. (2026). Optieum Biotechnologies — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/optieum-biotechnologies
{{cite web |title=Optieum Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/optieum-biotechnologies |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated